New drugs for colorectal cancer (irinotecan, oxaliplatin, raltitrexed) meet expectations in routine practice: A single center’s experience before and after their introduction

Author： Egreteau Joëlle   Boucher Eveline   Guibert Sophie   Jacquelinet Christian   Meunier Bernard   Boudjema Karim   Raoul Jean-Luc  

Publisher： Humana Press, Inc

ISSN： 1537-3649

Source： International Journal of Gastrointestinal Cancer, Vol.35, Iss.1, 2005-02, pp. : 69-76

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Predictors of Severe Toxicity in Patients Treated with Combination Chemotherapy with Irinotecan and/or Oxaliplatin for Metastatic Colorectal Cancer: A Single Center Experience

By  

Medical Oncology, Vol. 23, Iss. 3, 2006-09 ,pp. : 347-358

Humana Press, Inc

Access to resources Recommend Favorite

Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil

By Pfeiffer Per   Nielsen Dorte   Yilmaz Mette   Iversen Anja   Vejlø Christian   Jensen Benny Vittrup  

Acta Oncologica, Vol. 46, Iss. 5, 2007-01 ,pp. : 697-701

Informa Healthcare

Access to resources Recommend Favorite

A Phase II Trial of Oxaliplatin, Folinic Acid, and 5-Fluorouracil (FOLFOX4) as First-Line Chemotherapy in Advanced Colorectal Cancer: A China Single-Center Experience

By Xu Nong   Fang Wei-Jia   Zhang Xiao-Chen   Yu Lan-Fang   Bao Han-Ying   Shi Gen-Ming   Huang Sui   Shen Peng  

Cancer Investigation, Vol. 25, Iss. 7, 2007-09 ,pp. : 599-605

Informa Healthcare

Access to resources Recommend Favorite

Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex ( R)) in advanced colorectal cancer

By Farrugia D.C.   Norman A.R.   Cunningham D.  

European Journal of Cancer, Vol. 34, Iss. 7, 1998-06 ,pp. : 987-991

Elsevier

Access to resources Recommend Favorite

Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer

By Park Sook   Hong Yong   Lim Hyeong-Seok   Seong Moon-Woo   Kong Sun-Young   Kim Sun   Park Young-Iee   Jung Kyung  

Cancer Chemotherapy and Pharmacology, Vol. 72, Iss. 5, 2013-11 ,pp. : 953-964

Springer Publishing Company

Access to resources Recommend Favorite